( )
Tailor-made antibodies to suit every client's needs
GENOVAC Antibody Technology supports all project types from reagent antibodies to diagnostic and therapeutic applications with high success rates. Based on many years of experience, our technology has been developed to cater for all protein targets where other methods have failed. Our custom antibodies have been validated in over 130 publications and patents for more than 500 clients worldwide.Learn more about our genetic, protein, and peptide immunization strategies. Please fill out the Aldevron Antibody Services Questionnaire today to see how we can best customize our services for you.
Additional services include antibody processing, production, labeling, characterization and sequencing. Contact Aldevron if you are interested in any additional antibody related services.
Ready-to-ship antibodies
Aldevron applies its unique antibody technology to develop its own catalog of highly specific monoclonal antibodies. Visit our ready-to-ship antibodies for more information.Du SX, et al (2009): Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. Virology, 395(1):33-44.
Hooper JW, et al (2008): Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. FJ Virol., 82(3):1332-8.
Elagoz A, et al (2004): A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor. Br J Pharmacol., 141(1):37-46.
| Project | Application | Aldevron's Advantage |
|---|---|---|
| Target extracellular domains of six GPCRs: FPRL1, RDC1, CXCR7, LGR4, LGR5 and LGR6 | Therapeutics and diagnostics | Allows generation of antagonistic antibodies against GPCRs with an unprecedented success rate |
| Block HCV entry into human liver cells | Potential HCV therapy | Allows generation of blocking antibodies:
|
| Differentiate two highly homologous cell surface receptors (Claudin 6 and 9) | Potential HCV therapy | Allows generation of antibodies specific of two highly conserved tetraspanin molecules (3 amino acid differences between the extracellular domains) |
| Generate antibodies against bacterial toxins (Clostridium botulinum neurotoxin light chain serotypes A and B) | Potential therapy | Allows generation of antibodies against toxic proteins |
| Differentiate epitopes with low immunogenicity | Target validation | Allows generation of antibodies against immunorecessive epitopes of CEACAM1 |
| REAGENTS THAT BIND CCX-CKR2 | |
| Publication/Patent number: | WO2006116319 |
| Publication date: | 2006-11-02 |
| Inventor: | Howard Maureen (US); Schall Thomas (US) |
| Applicant: | Chemocentryx Inc (US); Howard Maureen (US); Schall Thomas (US) |
| Antigen: | neutralizing monoclonal antibody against CCX-CKR2 / RDC1 |
| ANTIBODIES THAT BIND CXCR7 EPITOPES | |
| Publication/Patent number: | US20090022717 |
| Publication date: | 2009-01-22 |
| Inventor: | Premack Brett (US); Miao Zhenhua (US); Penfold Mark (US) |
| Applicant: | ChemoCentryx, Inc. (US) |
| Antigen: | neutralizing monoclonal antibody against CXCR7 |
| A METHOD FOR IDENTIFYING, EXPANDING, AND REMOVING ADULT STEM CELLS AND CANCER STEM CELLS | |
| Publication/Patent number: | WO2009022907 |
| Publication date: | 2009-02-19 |
| Inventor: | Clevers Johannes Carolus [NL]; Barker Nicholas [NL]; Haegebarth Andrea [DE]; Van De Wetering Marcus Lambertus [NL] |
| Applicant: | Hubrecht Inst [NL]; Konink NL Akademie Van Wetensc [NL]; Clevers Johannes Carolus [NL]; Barker Nicholas [NL]; Haegebarth Andrea [DE]; Van De Wetering Marcus Lambertus [NL] |
| Antigen: | LGR5 (GPR49) and LGR6 |
| ANTIBODIES RECOGNIZING ENDOGENOUS HUMAN LGR5 AND/OR LGR6 | |
| Publication/Patent number: | WO2010016766 |
| Publication date: | 2010-02-11 |
| Inventor: | CLEVERS JOHANNES CAROLUS [NL]; BARKER NICHOLAS [NL]; HAEGEBARTH ANDREA [DE]; VAN DE WETERING MARCUS LAMBERTUS [NL] |
| Applicant: | KONINK NL AKADEMIE VAN WETENSC [NL]; KONINK NL AKADEMIE VAN WETENSC [NL]; HUBRECHT LAB [NL]; CLEVERS JOHANNES CAROLUS [NL]; BARKER NICHOLAS [NL]; HAEGEBARTH ANDREA [DE]; VAN DE WETERING MARCUS LAMBERT [NL] |
| Antigen: | LGR5 and LGR6 |
| MONOCLONAL ANTI-CLAUDIN 1 ANTIBODIES FOR THE INHIBITION OF HEPATITIS C VIRUS INFECTION | |
| Publication/Patent number: | WO2010034812 |
| Publication date: | 2010-04-01 |
| Inventor: | BAUMERT THOMAS [FR]; SCHUSTER CATHERINE [FR]; THOMPSON JOHN [DE]; GRUNERT FRITZ [DE] |
| Applicant: | INST NAT SANTE RECH MED [FR]; GENOVAC [DE]; UNIV STRASBOURG [FR]; BAUMERT THOMAS [FR]; SCHUSTER CATHERINE [FR]; THOMPSON JOHN [DE]; GRUNERT FRITZ [DE] |
| Antigen: | Claudin 1 |
Genetic immunization allowed generation of mAbs that differentiate
two highly conserved tetraspanin molecules (Claudin 6 and Claudin 9).
Study completed in collaboration with INSERM (Strasbourg, France)